MethylGene, Otsuka Collaborate To Develop Kinase Inhibitors For Ocular Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth potential $55 million expands MethylGene’s therapeutic research, development into ocular diseases.
You may also be interested in...
Otsuka, Justice Dept. Settle Charges For Off-Label Abilify Marketing
Japanese pharma agrees to pay $4 million to state and federal agencies.
Otsuka, Justice Dept. Settle Charges For Off-Label Abilify Marketing
Japanese pharma agrees to pay $4 million to state and federal agencies.
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.